BRITISH AMERICAN TOBACCO: NAVIGATING THE ENDGAME

A Macro Intelligence Memo | June 2030 | CEO Edition

From: The 2030 Report Date: June 2030 Re: BAT - Leadership in the Terminal Decline of a Legacy Business

Executive Summary

The CEO of BAT between 2024-2030 had the perhaps the most existentially challenging job in the sample: managing a business that was fundamentally declining while trying to transition to new products before the decline became unmanageable.

The Fundamental Dilemma

In 2024, BAT's CEO faced an awkward truth: the traditional cigarette business was dying. The company generated enormous cash from this business, but the trend was inexorably downward.

The CEO's strategic choice: milk the declining business for cash while investing aggressively in smoke-free products in hopes of creating a successor business before the core business became too small to fund dividends.

This required discipline and patience. The temptation was to cut costs in traditional cigarettes to maximize short-term cash. But cutting too aggressively would accelerate decline and damage the brand.

The CEO had to balance short-term cash generation with medium-term transition, all while managing shareholder expectations and board pressure.

The Smoke-Free Bet

Between 2024-2030, BAT invested approximately $8-10 billion in developing and marketing smoke-free products.

This was significant capital. The question was whether these investments would generate sufficient returns to justify the capital expenditure and to eventually replace the declining cigarette business.

By 2028, it was clear that the transition was slower than the company had hoped. Smoke-free products were growing, but not fast enough to offset cigarette decline.

The CEO was forced to make a difficult realization: the company wouldn't have a pure smoke-free successor to cigarettes. BAT would remain a hybrid business with declining traditional business and slower-than-hoped smoke-free growth.

The Regulation Management

Running BAT also meant constant engagement with regulators, who were increasingly hostile to the business.

The CEO had to navigate an environment where regulators were actively trying to restrict the company's business through taxation, marketing restrictions, product bans, and age restrictions.

This was different from most regulatory challenges. BAT wasn't being regulated, it was being legislatively constrained.

The CEO's approach was to be pragmatic: comply with regulations, minimize litigation, and invest in markets where regulation was less restrictive.

But this also meant accepting that BAT's addressable market was shrinking. The company couldn't grow in developed markets. Growth could only come from emerging markets with lower regulatory intensity.

The Diversification Question

Some board members pushed the CEO to diversify BAT beyond tobacco—to acquire non-tobacco businesses that could generate returns and provide hedge against declining cigarette business.

The CEO resisted this. The logic: BAT's strength was in understanding smokers and in distribution networks for consumer products. Diversifying into unrelated businesses would dilute focus and wouldn't leverage these strengths.

Instead, the CEO pushed for deeper smoke-free diversification—investing in nicotine delivery systems that leveraged BAT's existing capabilities.

This was a bet that BAT could transition from cigarettes to diversified nicotine products while remaining in the nicotine business rather than exiting.

The Dividend Commitment

One of the CEO's most important decisions was the commitment to maintain dividend levels despite declining volumes.

This was necessary for investor retention. If BAT cut the dividend, the stock would crater, and the company's cost of capital would rise.

The CEO committed to using share buybacks to manage the stock price if necessary and to cutting costs to preserve cash for dividends.

Between 2024-2030, BAT did indeed increase buyback activity, effectively returning more capital to shareholders while reducing the share count.

This worked in terms of maintaining stock price, but it also meant the company was returning more capital than it was reinvesting in the business—a signal of a mature, declining business managing decline.

The ESG Tension

By 2030, BAT faced an uncomfortable ESG (environmental, social, governance) question.

The company's traditional business—selling addictive products—was inherently at odds with modern ESG frameworks. No amount of smoke-free product development would resolve this fundamental tension.

Some institutional investors were divesting from BAT on ESG grounds. The CEO had to decide whether to fight this (trying to convince investors that BAT was ethical) or to accept it (acknowledging that some investors would never invest in tobacco).

The CEO generally accepted it. The company couldn't reasonably claim to be ethical while making the bulk of profits from cigarette sales.

The 2030 Assessment

By June 2030, the CEO who had navigated BAT through this period had successfully managed a difficult transition.

The company remained profitable. Dividends were maintained. The smoke-free business had grown (though not as fast as hoped).

But the CEO was essentially managing the orderly decline of a legacy business. This wasn't a failure—the company was doing as well as could be expected given the structural headwinds.

But it was a finite strategy. By 2035-2040, if trends continued, BAT would either need to have successfully transitioned to smoke-free or would need to accept significantly lower profitability.

The CEO had bought time but hadn't solved the fundamental problem.

Key Takeaway

The BAT case shows that leadership in declining businesses is about managing expectations and maximizing cash generation from a shrinking core while investing carefully in potential successors.

It's not glamorous, but it's necessary. The CEO couldn't prevent decline, but could manage it responsibly.

Word Count: 904